Beilstein J. Org. Chem.2018,14, 436–469, doi:10.3762/bjoc.14.32
group; oligonucleotide prodrugs; reduction-responsive; stimuli-responsivenucleicacids; thermolytic prodrugs; Introduction
For past decades, oligonucleotide-based therapies have been widely developed using short synthetic oligonucleotides (ONs) and their chemically modified mimics as powerful tools to
PDF
Graphical Abstract
Scheme 1:
Demasking under reducing agents of ON prodrugs modified as phosphotriesters with A) benzyl groups [13] ...